Insight Molecular Diagnostics (IMDX) Income from Continuing Operations (2015 - 2026)

Insight Molecular Diagnostics has disclosed Income from Continuing Operations across 12 years of filings, most recently posting 4413000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 4413000.0, up 35.09% year-over-year; the trailing twelve-month figure through Mar 2026 was 8161000.0 (up 20.54% YoY), and the FY2025 annual result was 10547000.0, up 17.21% from the prior year.
• Income from Continuing Operations came in at 4413000.0 for Q1 2026 at Insight Molecular Diagnostics, down from 17142000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 17142000.0 in Q4 2025 to a low of 15992000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 6489000.0 (2023), against an average of 4178117.65.
• Peak annual rise in Income from Continuing Operations reached 274.6% in 2023, while the deepest fall reached 510.92% in 2023.
• Insight Molecular Diagnostics' Income from Continuing Operations stood at 12017000.0 in 2022, then slumped by 33.08% to 15992000.0 in 2023, then soared by 191.76% to 14675000.0 in 2024, then advanced by 16.81% to 17142000.0 in 2025, then tumbled by 125.74% to 4413000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 4413000.0 (Q1 2026), 17142000.0 (Q4 2025), and 11048000.0 (Q3 2025), per Business Quant data.